China assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, Evaluate said. Daiichi Sankyo named former Novartis exec John Tsai, M.D., as its new R&D head. Astellas is committing up to $1.7 billion to partner on Vir Biotechnology's PSMA-targeting T-cell engager. And more.
